Regeneron Shares 4.8% Off 52-Week High with 11.3% Analyst Upside
Regeneron’s shares are down 4.8% from their 52-week high of $821.11 and have gained 11.2% over the past year versus the Nasdaq’s 22.2% return. Analysts maintain a consensus Strong Buy with a mean price target of $870.35, implying 11.3% upside.
1. Stock Performance Trends
Regeneron’s shares currently stand 4.8% below their 52-week high of $821.11, having gained 11.2% over the past year versus the Nasdaq’s 22.2% return. On a year-to-date basis, the stock is up 1.3% while the Nasdaq Composite is down 2.5%. It has traded above its 50-day moving average since mid-July 2025 and above its 200-day average since late October.
2. Regulatory and Pipeline Catalysts
Positive regulatory developments and label expansions for key products such as Eylea HD have driven investor optimism. Continued robust sales growth for immunology leader Dupixent and oncology treatment Libtayo has further supported the stock’s momentum.
3. Analyst Consensus and Price Targets
Analyst coverage remains bullish, with a consensus Strong Buy rating from 27 analysts and a mean price target of $870.35, implying an 11.3% premium to current levels. This projection reflects confidence in upcoming trial readouts and additional label expansions.
4. Peer Comparison
Despite its strong fundamentals, Regeneron has underperformed biotechnology peer Amgen, whose shares rose 26.9% over the past 52 weeks and 18.6% year-to-date. The disparity highlights differing investor sentiment and pipeline milestones across the sector.